Comparative Study
doi: 10.1001/archpsyc.63.10.1074.
Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
Affiliations
- PMID: 17015809
- DOI: 10.1001/archpsyc.63.10.1074
Item in Clipboard
Comparative Study
Outcomes, costs, and policy caution. A commentary on: the Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1)
Arch Gen Psychiatry.
2006 Oct.
No abstract available
Comment in
-
CUtLASS confirms CATIE.Arch Gen Psychiatry. 2007 Aug;64(8):978; author reply 979-80. doi: 10.1001/archpsyc.64.8.978-a. Arch Gen Psychiatry. 2007. PMID: 17679644 No abstract available.
Comment on
-
Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).Arch Gen Psychiatry. 2006 Oct;63(10):1079-87. doi: 10.1001/archpsyc.63.10.1079. Arch Gen Psychiatry. 2006. PMID: 17015810 Clinical Trial.
Similar articles
-
Comparative effectiveness of antipsychotic drugs. A commentary on: Cost Utility Of The Latest Antipsychotic Drugs In Schizophrenia Study (CUtLASS 1) and Clinical Antipsychotic Trials Of Intervention Effectiveness (CATIE).Arch Gen Psychiatry. 2006 Oct;63(10):1069-72. doi: 10.1001/archpsyc.63.10.1069. Arch Gen Psychiatry. 2006. PMID: 17015808 No abstract available.
-
The costs of drugs for schizophrenia.Am J Psychiatry. 2006 Dec;163(12):2029-31. doi: 10.1176/ajp.2006.163.12.2029. Am J Psychiatry. 2006. PMID: 17151146 No abstract available.
-
Cost-effectiveness of schizophrenia pharmacotherapy.Am J Psychiatry. 2007 Apr;164(4):678; author reply 678-9. doi: 10.1176/ajp.2007.164.4.678a. Am J Psychiatry. 2007. PMID: 17403984 No abstract available.
-
Clinical trial-based cost-effectiveness analyses of antipsychotic use.Am J Psychiatry. 2006 Dec;163(12):2047-56. doi: 10.1176/appi.ajp.163.12.2047. Am J Psychiatry. 2006. PMID: 17151153 Review.
-
Antipsychotics and schizophrenia: from efficacy and effectiveness to clinical decision-making.Can J Psychiatry. 2010 Mar;55(3):117-25. doi: 10.1177/070674371005500302. Can J Psychiatry. 2010. PMID: 20370961 Review.
Cited by
-
Pharmacotherapy of schizophrenic patients: preponderance of off-label drug use.PLoS One. 2008 Sep 10;3(9):e3150. doi: 10.1371/journal.pone.0003150. PLoS One. 2008. PMID: 18781198 Free PMC article.
-
Duration of pharmacotherapy with long-acting injectable risperidone in the treatment of schizophrenia.Psychiatr Q. 2009 Dec;80(4):241-9. doi: 10.1007/s11126-009-9111-9. Epub 2009 Sep 19. Psychiatr Q. 2009. PMID: 19768543
-
Do effectiveness ("real world") studies on antipsychotics tell us the real truth?Eur Arch Psychiatry Clin Neurosci. 2008 Aug;258(5):257-70. doi: 10.1007/s00406-008-0812-0. Epub 2008 Jul 11. Eur Arch Psychiatry Clin Neurosci. 2008. PMID: 18622639 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
